Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval
📍Bristol Myers Squibb (BMS) has announced that an injectable form of its cancer immunotherapy Opdivo (nivolumab) has been approved by the US Food and Drug Administration (FDA). 🔹Opdivo Qvantig, which co-formulates nivolumab with recombinant human hyaluronidase, has been authorised for subcutaneous (SC) use in most previously approved adult, solid tumour intravenous (IV) Opdivo indications. 🔹This … Read more